



beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium 172mcg / 5mcg / 9mcg (Trimbow®)

Chiesi Limited

5 February 2021 (*Issued 8 July 2022*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium (Trimbow®) is accepted for use within NHSScotland.

Indication under review: maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year

Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trimbow®) offers an additional treatment choice of high dose inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) in a single inhaler. SMC has previously accepted an alternative LAMA as an add-on treatment to ICS and LABA in asthma.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Published 08 August 2022

*This assessment is based on data submitted by the applicant company up to and including **25 January 2021.***

Chairman
Scottish Medicines Consortium